Skip to main content

Advertisement

SpringerLink
Log in

How Long to Treat with Denosumab

  • Therapeutics and Medical Management (E Shane and R Adler, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Chronic diseases typically require long-term treatment. Osteoporosis is a chronic disease in which fracture risk is high, and treatment is required to prevent fragility fractures. Denosumab is a fully human monoclonal antibody that inhibits RANK ligand, a powerful bone-resorbing cytokine. It is approved for individuals with osteoporosis who are at high risk for fracture. Clinical trial results confirm that denosumab is effective over the long term and has an excellent safety profile. In patients at high risk for osteoporotic fracture, therefore, long-term treatment with denosumab appears to present an attractive benefit profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Day JC. Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. Washington: U.S. Government Printing Office; 1996.

    Google Scholar 

  2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.

    Article  PubMed  Google Scholar 

  3. Kanis JA, Geusens P, Christiansen C. Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1991;1(3):182–8.

    Article  CAS  PubMed  Google Scholar 

  4. Melton 3rd LJ. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18(6):1139–41.

    Article  PubMed  Google Scholar 

  5. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 152(6):380–90.

  6. Lewiecki EM. Denosumab update. Curr Opin Rheumatol. 2009;21(4):369–73.

    Article  PubMed  Google Scholar 

  7. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–57.

    Article  CAS  PubMed  Google Scholar 

  8. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–31.

    Article  CAS  PubMed  Google Scholar 

  9. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832–41.

    Article  CAS  PubMed  Google Scholar 

  10. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

    Article  CAS  PubMed  Google Scholar 

  11. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Bolognese MA, Teglbjaerg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom. 2013;16(2):147–53.

    Article  PubMed  Google Scholar 

  13. Keaveny T, McClung M, Genant H, Zanchetta J, Kendler D, Brown J, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2013.

  14. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161–9.

    Article  CAS  PubMed  Google Scholar 

  15. Langdahl BL, Teglbjaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100(4):1335–42.

    Article  CAS  PubMed  Google Scholar 

  16. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701. This clinical trial presented data on the effects of 5-year denosumab treatment on BTMs and bone density.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–7. This clinical trial presented data on the effect of denosumab treatment on BTMs.

    Article  CAS  PubMed  Google Scholar 

  18. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis international. 2015. This article presents data from patients who have taken denosumab for up to 8 years.

  19. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9. The reversibility of denosumab treatment is described in this study.

    Article  CAS  PubMed  Google Scholar 

  21. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81.

    Article  CAS  PubMed  Google Scholar 

  22. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256–65.

    Article  CAS  PubMed  Google Scholar 

  23. Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29(9):2051–6. This article discusses the effect of long-term teatment with denosumab on bone histology and histomorphometry.

    Article  CAS  PubMed  Google Scholar 

  24. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int. 2011;22(2):435–46.

    Article  CAS  PubMed  Google Scholar 

  25. Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2015.

  26. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.

    Article  PubMed  Google Scholar 

  27. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab—a case report. Acta Orthop. 2014;85(1):6–7.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013;2013:249872.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab. 2015;33(3):355–8.

    Article  CAS  PubMed  Google Scholar 

  30. Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab—a case report. Bone. 2014;61:44–7.

    Article  PubMed  Google Scholar 

  31. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.

    Article  CAS  PubMed  Google Scholar 

  32. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–65.

    Article  CAS  PubMed  Google Scholar 

  33. Brown JP, Roux C, Torring O, Ho PR, Beck Jensen JE, Gilchrist N, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Brown JP, Dempster DW, Ding B, Dent-Acosta R, San Martin J, Grauer A, et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res. 2011;26(11):2737–44.

    Article  CAS  PubMed  Google Scholar 

  35. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.

    Article  PubMed  Google Scholar 

  37. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.

    Article  PubMed  Google Scholar 

  38. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, 630 West 168th Street PH8W-864, New York, NY, 10032, USA

    Aline G. Costa & John P. Bilezikian

Authors
  1. Aline G. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Bilezikian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Bilezikian.

Ethics declarations

Conflict of Interest

The authors state no conflict of interests.

Human and Animal Rights and Informed Consent

This article contains no studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Therapeutics and Medical Management

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costa, A.G., Bilezikian, J.P. How Long to Treat with Denosumab. Curr Osteoporos Rep 13, 415–420 (2015). https://doi.org/10.1007/s11914-015-0295-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-015-0295-7

Keywords

Search

Navigation